SI1940786T1 - Bifenilni derivati in njihova uporaba pri zdravljenju hepatitisa C - Google Patents
Bifenilni derivati in njihova uporaba pri zdravljenju hepatitisa CInfo
- Publication number
- SI1940786T1 SI1940786T1 SI200630798T SI200630798T SI1940786T1 SI 1940786 T1 SI1940786 T1 SI 1940786T1 SI 200630798 T SI200630798 T SI 200630798T SI 200630798 T SI200630798 T SI 200630798T SI 1940786 T1 SI1940786 T1 SI 1940786T1
- Authority
- SI
- Slovenia
- Prior art keywords
- treating hepatitis
- biphenyl derivatives
- hepatitis
- biphenyl
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0518971.7A GB0518971D0 (en) | 2005-09-16 | 2005-09-16 | Chemical compounds |
GB0610664A GB0610664D0 (en) | 2006-05-30 | 2006-05-30 | Chemical compounds |
GB0610663A GB0610663D0 (en) | 2006-05-30 | 2006-05-30 | Chemical compounds |
EP06779478A EP1940786B1 (en) | 2005-09-16 | 2006-09-18 | Biphenyl derivatives and their use in treating hepatitis c |
PCT/GB2006/003469 WO2007031791A1 (en) | 2005-09-16 | 2006-09-18 | Biphenyl derivatives and their use in treating hepatitis c |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1940786T1 true SI1940786T1 (sl) | 2010-11-30 |
Family
ID=37398704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200630798T SI1940786T1 (sl) | 2005-09-16 | 2006-09-18 | Bifenilni derivati in njihova uporaba pri zdravljenju hepatitisa C |
Country Status (23)
Country | Link |
---|---|
US (1) | US8008303B2 (sl) |
EP (1) | EP1940786B1 (sl) |
JP (1) | JP2009508835A (sl) |
KR (1) | KR20080050490A (sl) |
AT (1) | ATE478044T1 (sl) |
AU (2) | AU2006290442B2 (sl) |
BR (1) | BRPI0615934A2 (sl) |
CA (1) | CA2621364A1 (sl) |
CY (1) | CY1110835T1 (sl) |
DE (1) | DE602006016313D1 (sl) |
DK (1) | DK1940786T3 (sl) |
EC (1) | ECSP088367A (sl) |
ES (1) | ES2348332T3 (sl) |
HK (1) | HK1121440A1 (sl) |
HR (1) | HRP20100542T1 (sl) |
IL (1) | IL189694A0 (sl) |
NO (1) | NO20081846L (sl) |
NZ (1) | NZ566276A (sl) |
PL (1) | PL1940786T3 (sl) |
PT (1) | PT1940786E (sl) |
RS (1) | RS51470B (sl) |
SI (1) | SI1940786T1 (sl) |
WO (1) | WO2007031791A1 (sl) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA93548C2 (uk) * | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
EP2054383A2 (en) | 2006-08-09 | 2009-05-06 | SmithKline Beecham Corporation | Novel compounds as antagonists or inverse agonists at opioid receptors |
US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7745636B2 (en) | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
PE20080769A1 (es) * | 2006-09-08 | 2008-08-14 | Novartis Ag | Derivados de biaril-sulfonamida |
US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
WO2009034390A1 (en) * | 2007-09-14 | 2009-03-19 | Arrow Therapeutics Limited | Heterocyclic derivatives and their use in treating hepatitis c |
EP2242751B1 (en) | 2008-02-12 | 2015-07-15 | Bristol-Myers Squibb Company | Heterocyclic derivatives as hepatitis c virus inhibitors |
US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
DE102008049675A1 (de) | 2008-09-30 | 2010-04-01 | Markus Dr. Heinrich | Verfahren zur Herstellung von 3-Aminobiphenylen |
US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
UY32462A (es) * | 2009-02-23 | 2010-09-30 | Arrow Therapeutics Ltd | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 |
KR20130130875A (ko) | 2009-02-27 | 2013-12-02 | 이난타 파마슈티칼스, 인코포레이티드 | C형 간염 바이러스 억제제 |
US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2011031934A1 (en) * | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP2013525448A (ja) * | 2010-04-27 | 2013-06-20 | カルシメディカ,インク. | 細胞内カルシウムを調節する化合物 |
EP2594554A4 (en) * | 2010-07-13 | 2014-01-15 | Dainippon Sumitomo Pharma Co | BIARYLAMID DERIVATIVES BZW. PHARMACEUTICALLY PERMITTED SALT FROM THIS |
US8921372B2 (en) * | 2010-11-04 | 2014-12-30 | Theravance Biopharma R&D Ip, Llc | Inhibitors of hepatitis C virus |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
RU2456266C1 (ru) * | 2011-04-06 | 2012-07-20 | Максим Эдуардович Запольский | Производные 4,4'-бифениламидов, обладающие фармакологической активностью, и лекарственные средства на их основе |
US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2751080B1 (en) * | 2011-08-31 | 2015-10-28 | Amakem NV | Novel soft rock inhibitors |
WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
TWI577672B (zh) | 2011-11-03 | 2017-04-11 | 施萬生物製藥研發Ip有限責任公司 | C型肝炎病毒抑制劑 |
WO2013096744A1 (en) | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
SG11201404475TA (en) | 2012-02-10 | 2014-08-28 | Lupin Ltd | Antiviral compounds with a dibenzooxaheterocycle moiety |
EP2820013B9 (en) | 2012-03-02 | 2019-01-09 | Ralexar Therapeutics, Inc. | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
AR091654A1 (es) * | 2012-07-02 | 2015-02-18 | Biogen Idec Inc | COMPUESTOS QUE CONTIENEN BIARILO COMO AGONISTAS INVERSOS DE RECEPTORES ROR-g |
CN104902885A (zh) | 2012-08-28 | 2015-09-09 | 爱尔兰詹森科学公司 | 氨磺酰基-芳基酰胺和其作为药物用于治疗乙型肝炎的用途 |
US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
CA2907528A1 (en) | 2013-03-20 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Novel compounds |
CA2922302C (en) | 2013-04-03 | 2021-08-03 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
LT3024819T (lt) | 2013-07-25 | 2018-06-11 | Janssen Sciences Ireland Uc | Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui |
MX2016002930A (es) | 2013-09-04 | 2016-12-02 | Ralexar Therapeutics Inc | Moduladores del receptor x hepatico (lxr). |
DK3041835T3 (da) | 2013-09-04 | 2020-07-13 | Ellora Therapeutics Inc | Modulatorer af lever-X-receptorer (LXR) |
KR102290189B1 (ko) | 2013-10-23 | 2021-08-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 카르복스아미드 유도체 및 b형 간염 치료용 의약으로서의 이의 용도 |
CN104725365B (zh) * | 2013-12-23 | 2019-02-26 | 南京圣和药业股份有限公司 | 丙型肝炎病毒抑制剂及其应用 |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
RU2702109C1 (ru) | 2014-02-05 | 2019-10-04 | Новира Терапьютикс, Инк. | Комбинированная терапия для лечения инфекций вгв |
EA035848B1 (ru) | 2014-02-06 | 2020-08-20 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
CN108064222A (zh) | 2015-02-20 | 2018-05-22 | 拜耳制药股份公司 | N-苯基-(吗啉-4-基或哌嗪基)乙酰胺衍生物及其作为wnt信号通路抑制剂的用途 |
EA201792069A1 (ru) | 2015-03-19 | 2018-04-30 | Новира Терапьютикс, Инк. | Производные азокана и азонана и способы лечения инфекций гепатита в |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AR106192A1 (es) | 2015-09-29 | 2017-12-20 | Novira Therapeutics Inc | Formas cristalinas de un agente antiviral contra la hepatitis b |
MA53755A (fr) | 2016-03-17 | 2021-08-04 | Hoffmann La Roche | Dérivé de 5-éthyl-4-méthyl-pyrazole-3-carboxamide ayant une activité comme agonist de taar |
AU2017248828A1 (en) | 2016-04-15 | 2018-11-01 | Janssen Sciences Ireland Uc | Combinations and methods comprising a capsid assembly inhibitor |
CN109641874A (zh) * | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
EP3641762A4 (en) | 2017-06-20 | 2021-03-10 | C4 Therapeutics, Inc. | N / O BONDED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION |
WO2019099868A2 (en) | 2017-11-16 | 2019-05-23 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
WO2019175657A1 (en) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
WO2020117849A1 (en) | 2018-12-04 | 2020-06-11 | Bristol-Myers Squibb Company | Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring |
AU2020223865A1 (en) | 2019-02-22 | 2021-07-15 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
MX2021013594A (es) | 2019-05-06 | 2021-12-10 | Janssen Sciences Ireland Unlimited Co | Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. |
CR20220178A (es) | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
US11851419B2 (en) | 2020-11-20 | 2023-12-26 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
AU2022263410A1 (en) | 2021-04-21 | 2023-10-05 | Gilead Sciences, Inc. | Carboxy-benzimidazole glp-1r modulating compounds |
WO2023158795A1 (en) * | 2022-02-18 | 2023-08-24 | Accent Therapeutics, Inc. | Inhibitors of rna helicase dhx9 and uses thereof |
WO2023212718A2 (en) * | 2022-04-29 | 2023-11-02 | Cornell University | Methods of treating a virus infection and methods of inhibiting viral replication |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5026940A (en) * | 1989-09-08 | 1991-06-25 | Catalytica, Inc. | Manufacture of 4,4'-diisopropylbiphenyl |
GB9119920D0 (en) * | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
JP2787539B2 (ja) | 1993-02-26 | 1998-08-20 | 松森 昭 | ウイルス性疾患の予防または治療剤 |
IL110159A0 (en) | 1993-06-30 | 1994-10-07 | Wellcome Found | Diaryl compounds, their preparation and pharmaceutical compositions containing them |
IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
EP0900081A4 (en) | 1996-04-03 | 2002-01-09 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
WO1999040075A1 (fr) | 1998-02-05 | 1999-08-12 | Takeda Chemical Industries, Ltd. | Derives de sulfamide, leur procede de production et leur utilisation |
US6586475B1 (en) | 1998-11-20 | 2003-07-01 | Takeda Chemical Industries, Ltd. | β-amyloid protein production/secretion inhibitors |
AUPP818099A0 (en) | 1999-01-14 | 1999-02-11 | Fujisawa Pharmaceutical Co., Ltd. | New n-containing heterocyclic compounds |
CA2385592C (en) | 1999-09-17 | 2011-01-11 | Bing-Yan Zhu | Benzamides and related inhibitors of factor xa |
CA2386474A1 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
US6433236B1 (en) * | 2000-03-21 | 2002-08-13 | Arteva North America S.A.R.L. | Acid catalyzed isomerization of substituted diaryls |
WO2002000606A1 (fr) | 2000-06-28 | 2002-01-03 | Takeda Chemical Industries, Ltd. | Compose biphenyle |
AU2002305450A1 (en) | 2001-05-08 | 2002-11-18 | Yale University | Proteomimetic compounds and methods |
EP1578898A2 (en) | 2001-07-13 | 2005-09-28 | Virtual Drug Development, Inc. | Nad synthetase inhibitors and uses thereof |
CA2458926A1 (en) | 2001-09-13 | 2003-03-13 | Genesoft Pharmaceuticals, Inc. | Methods of treating infection by drug resistant bacteria |
GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124928D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
CA2473740A1 (en) | 2002-01-18 | 2003-07-31 | David Solow-Cordero | Methods of treating conditions associated with an edg receptor |
PT1474395E (pt) | 2002-02-12 | 2008-01-02 | Smithkline Beecham Corp | Derivados de nicotinamida úteis como inibidores de p38 |
GB0209891D0 (en) * | 2002-04-30 | 2002-06-05 | Glaxo Group Ltd | Novel compounds |
AU2003240488A1 (en) * | 2002-06-04 | 2003-12-19 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents |
US20060004010A1 (en) * | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
US7312227B2 (en) | 2002-11-01 | 2007-12-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
AU2004228028B2 (en) | 2003-04-03 | 2009-12-10 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
AU2004230889B2 (en) * | 2003-04-07 | 2008-03-13 | Pharmacyclics Llc | Hydroxamates as therapeutic agents |
GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
EP1653968A4 (en) * | 2003-07-23 | 2006-09-06 | Synta Pharmaceuticals Corp | METHOD FOR MODULATING CALCIUMION RELIEF ACTIVATED CALCIUMION CHANNELS |
ES2315703T3 (es) * | 2003-07-25 | 2009-04-01 | Novartis Ag | Inhibidores de la quinasa p-38. |
US20050054691A1 (en) | 2003-08-29 | 2005-03-10 | St. Jude Children's Research Hospital | Carboxylesterase inhibitors |
BRPI0414313A (pt) | 2003-09-11 | 2006-11-07 | Kemia Inc | inibidores de citocinas |
US20070099938A1 (en) * | 2003-10-24 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | Antistress drug and medical use thereof |
US7585997B2 (en) | 2003-12-31 | 2009-09-08 | Chesterford Enterprises Limited | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof |
ES2433466T3 (es) | 2004-02-27 | 2013-12-11 | Amgen, Inc | Compuestos, composiciones farmacéuticas y métodos para su uso en el tratamiento de trastornos metabólicos |
TW200600492A (en) | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
US20100234409A1 (en) | 2004-05-21 | 2010-09-16 | Lihu Yang | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity |
RU2007107349A (ru) * | 2004-07-28 | 2008-09-10 | Глэксо Груп Лимитед (GB) | Пиперазиновые производные, применение для лечения желудочно-кишечных расстройств |
MX2007001215A (es) | 2004-08-06 | 2007-04-17 | Otsuka Pharma Co Ltd | Compuestos aromaticos. |
CA2581489A1 (en) | 2004-10-06 | 2006-04-13 | Recepticon Aps | Use of compounds for the prevention of drug-induced cell toxicity |
US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
WO2006083477A2 (en) * | 2005-01-07 | 2006-08-10 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
JP2008531596A (ja) * | 2005-02-25 | 2008-08-14 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Hcv感染を治療または予防するのに有用なベンゾイソチアゾール |
WO2006102760A1 (en) | 2005-04-01 | 2006-10-05 | Methylgene Inc. | Inhibitors of histone deacetylase |
JP2009501721A (ja) | 2005-07-12 | 2009-01-22 | アカディア ファーマシューティカルズ インコーポレイテッド | レチノイン酸受容体における活性を伴う化合物 |
JP5430943B2 (ja) | 2006-01-25 | 2014-03-05 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫関連用途のための置換芳香族化合物 |
UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
WO2007103162A2 (en) | 2006-03-01 | 2007-09-13 | Samaritan Pharmaceuticals, Inc. | Structure based drug design of steroidogenesis inhibitors |
JP2009538890A (ja) | 2006-05-30 | 2009-11-12 | アロー セラピューティクス リミテッド | ビフェニル誘導体及びc型肝炎の治療におけるそれらの使用 |
UA95978C2 (ru) | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
WO2008046216A1 (en) | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
CA2913963A1 (en) | 2006-12-08 | 2008-06-19 | Millenium Pharmaceuticals, Inc. | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor |
US20090016990A1 (en) | 2007-01-24 | 2009-01-15 | Alberte Randall S | Antimicrobial Compositions |
WO2008147864A2 (en) | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
WO2009034390A1 (en) | 2007-09-14 | 2009-03-19 | Arrow Therapeutics Limited | Heterocyclic derivatives and their use in treating hepatitis c |
-
2006
- 2006-09-18 SI SI200630798T patent/SI1940786T1/sl unknown
- 2006-09-18 PT PT06779478T patent/PT1940786E/pt unknown
- 2006-09-18 RS RSP-2010/0437A patent/RS51470B/en unknown
- 2006-09-18 AU AU2006290442A patent/AU2006290442B2/en not_active Ceased
- 2006-09-18 JP JP2008530624A patent/JP2009508835A/ja active Pending
- 2006-09-18 KR KR1020087008964A patent/KR20080050490A/ko not_active Application Discontinuation
- 2006-09-18 WO PCT/GB2006/003469 patent/WO2007031791A1/en active Application Filing
- 2006-09-18 ES ES06779478T patent/ES2348332T3/es active Active
- 2006-09-18 EP EP06779478A patent/EP1940786B1/en active Active
- 2006-09-18 PL PL06779478T patent/PL1940786T3/pl unknown
- 2006-09-18 BR BRPI0615934-6A patent/BRPI0615934A2/pt not_active IP Right Cessation
- 2006-09-18 US US12/066,983 patent/US8008303B2/en not_active Expired - Fee Related
- 2006-09-18 CA CA002621364A patent/CA2621364A1/en not_active Abandoned
- 2006-09-18 AT AT06779478T patent/ATE478044T1/de active
- 2006-09-18 DK DK06779478.4T patent/DK1940786T3/da active
- 2006-09-18 DE DE602006016313T patent/DE602006016313D1/de active Active
- 2006-09-18 NZ NZ566276A patent/NZ566276A/en unknown
-
2008
- 2008-02-21 IL IL189694A patent/IL189694A0/en unknown
- 2008-04-14 EC EC2008008367A patent/ECSP088367A/es unknown
- 2008-04-16 NO NO20081846A patent/NO20081846L/no not_active Application Discontinuation
- 2008-11-24 HK HK08112854.2A patent/HK1121440A1/xx unknown
-
2010
- 2010-10-05 HR HR20100542T patent/HRP20100542T1/hr unknown
- 2010-10-14 CY CY20101100915T patent/CY1110835T1/el unknown
- 2010-10-29 AU AU2010238549A patent/AU2010238549A1/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
NO20081846L (no) | 2008-06-04 |
NZ566276A (en) | 2011-03-31 |
HK1121440A1 (en) | 2009-04-24 |
EP1940786B1 (en) | 2010-08-18 |
DK1940786T3 (da) | 2010-11-08 |
KR20080050490A (ko) | 2008-06-05 |
AU2006290442A1 (en) | 2007-03-22 |
IL189694A0 (en) | 2008-06-05 |
EP1940786A1 (en) | 2008-07-09 |
RS51470B (en) | 2011-04-30 |
PT1940786E (pt) | 2010-10-04 |
AU2010238549A1 (en) | 2010-11-18 |
HRP20100542T1 (hr) | 2010-11-30 |
BRPI0615934A2 (pt) | 2011-05-31 |
JP2009508835A (ja) | 2009-03-05 |
PL1940786T3 (pl) | 2010-12-31 |
AU2006290442B2 (en) | 2010-07-29 |
US20080255105A1 (en) | 2008-10-16 |
ES2348332T3 (es) | 2010-12-02 |
WO2007031791A1 (en) | 2007-03-22 |
US8008303B2 (en) | 2011-08-30 |
CY1110835T1 (el) | 2015-06-10 |
ATE478044T1 (de) | 2010-09-15 |
CA2621364A1 (en) | 2007-03-22 |
DE602006016313D1 (de) | 2010-09-30 |
ECSP088367A (es) | 2008-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL189694A0 (en) | Biphenyl derivatives and their use in treating hepatitis c | |
MY146111A (en) | Acylaminopyrazoles as fgfr inhibitors | |
TW200738725A (en) | Unsaturated mTOR inhibitors | |
MY148688A (en) | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors | |
JO2848B1 (en) | Organic compounds | |
UA84712C2 (en) | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors | |
TW200801006A (en) | Fused bicyclic mTOR inhibitors | |
TW200740776A (en) | N-phenylbenzotriazolyl c-kit inhibitors | |
HK1112910A1 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
MX2009009473A (es) | Compuestos para el tratamiento de hepatitis c. | |
GB0413087D0 (en) | Therapeutic compounds | |
GEP20094638B (en) | Benzimidazolone carboxylic acid derivatives | |
WO2005021544A3 (en) | N3-substituted imidazopyridine-derivatives as c-kit inhibitors | |
TW200800969A (en) | Compounds | |
EP2639229A3 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
IL191751A0 (en) | Pyrrolo[2,3-c]pyridine derivatives | |
MX2010008226A (es) | Derivados de difluorobifenilamida para el tratamiento de hipertension ocular. | |
UA96304C2 (en) | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | |
PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
TNSN08369A1 (en) | Benzimidazole derivatives | |
WO2007131907A3 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
DE602006002608D1 (de) | 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit | |
IL191928A0 (en) | Triazoloanilinopyrimidine derivatives for use as antiviral agents | |
TW200738611A (en) | 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments | |
MX2009005912A (es) | Derivados de etilamina-fenilo heterociclilo sustituidos, su preparacion y uso como medicamentos. |